// App-Quantinova.ai

DOP70 : An integrated multi-omics biomarker predicting endoscopic response in ustekinumab treated patients with Crohn's disease

Researchers

Presenter

  • B Verstockt

Principal Investigators

  • P Sudahakar

  • B Creyns

  • S Verstockt

  • J Cremer

  • W-J Wollants

  • S Organe

  • T Korcsmaros

  • M Madgwick

  • G Van Assche

  • C Breynaert

  • S Vermeire

  • M Ferrante

Medical Centers

  • University Hospital CHU of Liege, Gastroenterology, Liege, Belgium

  • KU Leuven, Department of Chronic Diseases- Metabolism and Ageing- Translational Research Center for Gastrointestinal Disorders TARGID, Leuven, Belgium

  • Earlham Institute, Norwich, UK

  • Quadram Institute, Norwich, Belgium

  • Microbiology and Immunology, Laboratory of Clinical Immunology, KU Leuven, Leuven, Belgium

  • Department of Human Genetics, Laboratory for Complex Genetics, KU Leuven, Leuven, Belgium

Locations

  • Belgium

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Crohn's disease

Biomarkers

  • Cluster of Differentiation 14

  • Cluster of Differentiation 4

Drug/Treatment

  • Ustekinumab

  • Tamsulosin Hydrochloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved